Ponezumab
Ponezumab
Ponezumab (pronounced poh-nez-uh-mab) is a monoclonal antibody designed for the treatment of Alzheimer's disease. It is developed by Pfizer, a multinational pharmaceutical company.
Etymology
The name "Ponezumab" is derived from the standard nomenclature for monoclonal antibodies. The suffix "-mab" is used for all these antibodies, while "Ponezu-" is a unique prefix chosen by the manufacturer.
Function
Ponezumab works by binding to amyloid beta, a protein that forms plaques in the brains of Alzheimer's patients. By binding to this protein, Ponezumab helps to prevent the formation of these plaques, potentially slowing the progression of the disease.
Clinical Trials
Ponezumab has undergone several clinical trials to test its efficacy and safety. In Phase II trials, it was found to be safe and well-tolerated, but did not show significant effects on cognitive function. Further trials are ongoing to determine its potential benefits and risks.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Amyloid beta: A protein that is thought to play a role in Alzheimer's disease.
- Clinical trial: A research study that tests how well new medical approaches work in people.
External links
- Medical encyclopedia article on Ponezumab
- Wikipedia's article - Ponezumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski